Priya is a mission-driven senior global healthcare executive offering dynamic leadership in public, private, and social sectors.
She uniquely combines strong commercial and operational leadership, with work and lived experience as a frontline physician, digital innovator and public health professional across five continents.
Priya is passionately committed to ensuring health is a driver for well-being of individuals and communities.
During her tenure at MSD, Priya has held various leadership positions where she excels in building and galvanizing high-performing and diverse teams and fostering strategic partnerships to deliver on MSD’s mission to improve and save lives.
Most recently, Priya was the global commercial leader for the GARDASIL/GARDASIL 9 franchise which she grew to become the world’s #1 vaccine.
Previous roles include Chief Behavioral Science Officer for Global Vaccines during Covid to address vaccination hesitancy, Managing Director for the South Africa and Sub-Saharan Africa regional cluster responsible for a full business turnaround and spin-off, Business Unit Director in the UK leading the merger of the new vaccines business back into MSD and supporting the UK government to launch a gender-neutral HPV vaccination national immunization program and Executive Director of MSD for Mothers, where she launched and led the 500 million dollar initiative focused on reducing maternal mortality, including launching the world’s first Development Impact Bond for healthcare in India.
Dr. Agrawal’s career started as an obstetrician and gynecologist in the UK. She holds degrees in medicine from the University of Cambridge and the University of Oxford and graduated with a Master’s from the Harvard School of Public Health (HSPH) on a Fulbright Scholarship.
Currently, Dr. Agrawal is a fellow of the Royal Society of Medicine and actively serves as Vice Chair of the boards of Pathfinder International and Hilleman Laboratories.
Through her leadership in Health Equity & Partnerships at MSD, Dr. Priya Agrawal continues to drive efforts across the enterprise to ensure underserved populations, particularly those in low and middle income countries, are able to benefit from our innovative vaccines and medicines. Her commercial experience, expertise in global public health, and dedication to improving healthcare outcomes make her an invaluable asset in advancing MSD’s mission and positively impacting global health.
Go Back
